Antibody Screening
Successful antibody discovery programs need to rapidly identify and characterize target-reactive candidates. This case study demonstrates how the iQue Advanced Flow Cytometry Platform can be used for target cell line generation, mouse sera evaluation and hybridoma library screening.
Applications for Antibody Screening
Rapid evaluation of clones transfected with a cell surface target antigen. Selection of healthy clones that express high levels of the target antigen ensure optimal performance in downstream hybridoma screens.
Increase Productivity
400 engineered cell clones screened for high surface expression of target antigen.
5 x 96 well plates run and analyzed in 1 hour.
Powerful, Multiplexed Screening Assay
Multiplex cell based assay enables single-step screening for cell lines that have healthy growth and express high levels of surface antigen.
Fast and Easy Visualization of Results
Use profile maps to visualize clones that express high levels of target antigen and have grown to high cell numbers.
Visualization of Screen Results for Generation of Target Cell Line
Results from the screen visualized using ForeCyt. Cells were transduced with lentivirus encoding target antigen, cultured under selection pressure, and sorted into 96 well plates. After cell growth, aliquots of cells were transferred to assay plates, and tested for surface antigen expression using a fluorescently tagged antibody specific to that antigen using the iQue Advanced Flow Cytometry Platform. Cell number was simultaneously measured as an indication of cell growth.
Profile maps show wells that contain high numbers of cells that also express high levels of the target antigen on their surface.
The plate view shows details of the expression levels of the target antigen on the surface of cells. Expression data from untransfected control cells is overlaid to easily visualize positive clones.
Large scale cell based experiment to identify immunized mice producing high levels of antibody against target antigens. Simultaneously testing sera from dozens of immunized mice improves chance of successfully generating hybridomas with optimal antibody reactivity.
Increase Productivity
Sera from 36 immunized mice tested for binding to cell surface target antigens.
Sera from mice pre- and post-immunization were tested in 8 fold dilutions in duplicate.
Powerful, Multiplexed Screening Assay
Multiplex cell based assay enables single-step screening for sera that bind to target antigens but not other antigens.
Fast and Easy Visualization of Results
Use heat maps to visualize mouse sera that have high titers of antibodies that bind to target antigens but not other antigens.
Visualization of Screen Results for Mouse Sera Evaluation
Results from the testing visualized using the HeatMap feature in ForeCyt. 3 cell lines were color coded with the fluorescent Cell Encoder dye, mixed together and dispensed into wells of 384 well plates. Serum samples were added to each well, followed by a fluorescent detection antibody and plates were analyzed using the iQue Advanced Flow Cytometry Platform. Sera from 36 mice pre-immunization and post-immunization with the target antigen were tested in duplicate in 8 fold dilutions.
Heatmaps show results for antibody binding to control cells, cells expressing target antigen and cells expressing a related but irrelevant antigen.
A high throughput, multiplexed screen that simultaneously tests for binding to target antigens but not control antigens. The entire screen and data analysis were completed in one day.
Increase Productivity
9600 hybridoma clones screened from 2 different immunized mice.
25 x 384 well plates run and analyzed in 1 day.
Powerful, Multiplexed Screening Assay
Multiplex cell based assay enables single-step screening for antibodies that bind to target antigens but not other antigens.
Fast and Easy Visualization of Results
28,800 data points instantly combined and processed into binding metrics.
53 hits visualized that bind to target but not control antigens.
Visualization of Screen Results for Hybridoma Library Screening
Results from the entire screen visualized using the Panorama feature in ForeCyt. 3 cell lines were color coded with the fluorescent Cell Encoder dye mixed together and dispensed into wells of 384 well plates. Hybridoma supernatants were added to each well, followed by a fluorescent detection antibody. 9,600 hybridomas were tested from 2 different mice immunized with cells expressing target antigen. The entire screen was completed in 1 day.
Heat maps (red) showing results for antibody binding to control cells, cells expressing target antigen and cells expressing a related but irrelevant antigen.
Profile maps (blue) combine the binding results to the three cell types, showing antibodies that bind to cells expressing the target antigen, but not to cells expressing an irrelevant antigen or to negative control cells.
Resources for Antibody Screening
Featured Resources
Related Research
Label-Free Affinity and Kinetic Characterization in Real-Time
To fully understand biomolecular binding interactions, it is essential to establish an in-depth understanding of the binding mechanisms and stability during drug discovery and development.
Evaluating affinity constants (KD) alongside association and dissociation rates (ka, kd) is crucial for lead selection, as drugs with similar affinities can exhibit diverse binding mechanisms and kinetics. Octet® label-free assays are valuable tools for characterizing biomolecules' affinity and kinetics in real-time.
Drug Discovery and Optimization
The process of lead selection and refinement plays a crucial role in identifying molecules that meet specific requirements and can be advanced to the next stage of the development workflow. In the case of biologics, lead selection involves screening biological molecules to identify those with the desired functional and biophysical characteristics, while optimization helps to enhance these properties.
Label-free assays improve the speed and efficiency of these processes. Biosensor assays are high-throughput and can be easily developed for various applications, such as affinity ranking, epitope binning of large antibody pools, Fc-receptor binding, glycosylation screening, antibody-antigen specificity, binding characterization, and titer analysis.
Analyte Concentration and Contaminant Detection
The Octet® BLI platform offers a range of analytical capabilities that can improve the efficiency and quality of biopharmaceutical drug development. These capabilities include screening samples during cell line development, monitoring product titer from bioreactors, determining the dynamic binding capacity of affinity resins, and characterizing purified products. Additionally, the Octet® BLI platform can quickly detect and monitor potential process-generated contaminants such as Host Cell Proteins (HCP) and Residual Protein A (RPA) with better precision and robustness than traditional enzyme-linked immunosorbent assays (ELISAs).
Simplifying the drug development workflow and reducing time-to-results, minimizes costs during the production of biopharmaceutical drugs while maintaining high standards of quality and safety.
